Enhancing Infectious Disease Diagnostics
Quest Diagnostics, a leading provider of diagnostic services, has made a strategic move by acquiring the US laboratory business of Oxford Immunotec, a renowned diagnostics company. This acquisition aims to expand access to innovative and reliable tuberculosis (TB) testing in the United States.
Broadening TB Testing Options
The acquisition will incorporate Oxford Immunotec‘s T-SPOT®.TB and Accutix™ testing services into Quest Diagnostics’ portfolio. These tests utilize advanced technology to detect TB infection and disease with greater accuracy and convenience compared to traditional skin tests.
Long-Term Partnership for Innovation
As part of the agreement, Oxford Immunotec will continue to supply T-SPOT.TB test kits to Quest Diagnostics, ensuring ongoing access to this cutting-edge technology. Additionally, the companies plan to collaborate strategically to drive further growth and innovation in TB testing.
Addressing Latent TB Infection
TB remains a significant public health concern, with an estimated 13 million latent TB cases in the US alone. Blood-based IGRA tests, such as T-SPOT.TB, offer a valuable tool for identifying individuals with latent TB infection, allowing for early intervention and treatment to prevent disease progression.
Choice and Convenience for Physicians
Quest Diagnostics’ commitment to providing choice to physicians is evident in their continued offering of QuantiFERON TB blood testing services. This allows healthcare providers to select the most appropriate TB testing method based on individual patient needs and preferences.
Quest Diagnostics’ Strategic Vision
This acquisition aligns with Quest Diagnostics’ strategy to enhance its infectious disease diagnostics capabilities and expand access to innovative testing solutions. By incorporating Oxford Immunotec‘s expertise, Quest Diagnostics aims to empower physicians with advanced tools for accurate and timely TB detection.
Oxford Immunotec’s Contribution
Oxford Immunotec‘s T-SPOT.TB test has gained recognition for its accuracy, reliability, and ease of use. By joining forces with Quest Diagnostics, Oxford Immunotec will significantly increase the reach of its innovative TB testing services, benefiting patients and healthcare professionals nationwide.
Conclusion
The acquisition of Oxford Immunotec‘s US laboratory business by Quest Diagnostics marks a significant step towards improving TB testing capabilities in the United States. By combining the expertise of both companies, patients and healthcare providers will have access to a wider range of advanced and reliable TB testing options, leading to improved diagnosis, treatment, and prevention of this infectious disease.
